Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Neoplasm, Residual × Tyrosine Kinase Inhibitors × Clear all

Phase

Phase 2/3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasm, Residual 1 NSCLC 1 Carcinoma, Hepatocellular 1

Interventions

venetoclax 1 sugemalimab 1 Tyrosine Kinase Inhibitors 1 Sorafenib 1 Methotrexate 1 Fish Oils 1 Docosahexaenoic Acids 1 Cytarabine 1 Aspirin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03624530 2018-08-10

Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants

Nanfang Hospital, Southern Medical University

Phase 2/3 Unknown

Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡